In mice with TKI-resistant lung tumors, WQQ-345 not only slowed tumor growth but actually caused regressions in combination with EGFR blockade—effectively re-sensitizing the tumors to the treatment they had previously evaded [11,74]. This evidence concerns the gene EGFR and neoplasm.